XM does not provide services to residents of the United States of America.

Southwest Airlines adopts 'poison pill' after Elliott pushes for changes



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Southwest Airlines adopts 'poison pill' after Elliott pushes for changes</title></head><body>

Updates with shares in paragraph 10

July 3 (Reuters) -Southwest Airlines LUV.N adopted a so-called "poison pill" to deter Elliott Investment Management from raising its stake in the carrier after the activist investor called for leadership changes following disappointing financial results.

The announcement comes days after Southwest CEO Bob Jordan said he would not resign in response to pressure from Elliott, which revealed a stake worth nearly $2 billion in the carrier last month.

"Southwest Airlines has made a good faith effort to engage constructively with Elliott Investment Management since its initial investment and remains open to any ideas for lasting value creation," Southwest Executive Chair Gary Kelly said in a statement on Wednesday.

Kelly said Southwest's board adopted the poison pill as Elliott could "significantly increase" its current stake of 11%.

Under the "poison pill" strategy, used by corporate boards to thwart hostile takeover bids, Southwest will issue one right for each share of common stock. The rights will initially trade with the carrier's common stock and will generally become exercisable if any person or group acquires 12.5% or more of the company's shares.

The right will allow holders to buy shares of common stock at a substantial discount.

Elliott's push for replacing CEO Jordan with an outside hire came after the carrier delivered lackluster results in recent quarters, partly because of delays in plane supply from Boeing BA.N.

Late in June, the company also flagged ongoing struggles with pricing in its second quarter due to difficulties in accurately predicting travel demand, inviting criticism from Elliott.

Elliott was not immediately available for comment on Wednesday.

Shares of the company were up less than 1% in early trade. The stock has lostnearly 22% of its valuein the past 12 months.



Reporting by Abhijith Ganapavaram and Ananta Agarwal in Bengaluru; Editing by Devika Syamnath

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.